Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03014063 · ClinicalTrials.gov registry record

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

A clinical trial of Septic Shock, sponsored by The Cleveland Clinic.

Completed
Registry status
18
Enrollment target
1
Study location

NCT03014063: Completed study of Septic Shock, sponsored by The Cleveland Clinic.

NCT03014063 is a study of Septic Shock that has completed, run by The Cleveland Clinic. The registered enrollment target is 18 participants, below the 5,058-participant average among 24 other Septic Shock trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03014063, a study of Septic Shock, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
18 participants
Enrollment target
1
Study location

Study Summary

This is a prospective observational cohort trial evaluating a single plasma vasopressin concentration in patients receiving exogenous, adjunctive vasopressin for septic shock. The trial is designed to determine whether plasma vasopressin concentration influences the likelihood of hemodynamic response to exogenous vasopressin therapy.

Conditions Studied

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2016-11
Est. Completion 2017-06
The Cleveland Clinic

688 total trials

What the finished NCT03014063 record still lists

NCT03014063 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 5,058-participant average among 24 other Septic Shock trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Septic Shock appearing as the primary indexed condition, and to 0 interventions.

NCT03014063 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT03014063 about?

NCT03014063 is a clinical study titled "Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock". This is a prospective observational cohort trial evaluating a single plasma vasopressin concentration in patients receiving exogenous, adjunctive vasopressin for septic shock. The trial is designed to determine whether plasma vasopressin concentration influences the likelihood of hemodynamic respons...

What is the current status of trial NCT03014063?

This trial is currently completed. The enrollment target is 18 participants. The study started on 2016-11. Estimated completion is 2017-06.

What conditions does trial NCT03014063 study?

This clinical trial studies the following conditions: Septic Shock.

Who is sponsoring clinical trial NCT03014063?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03014063 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Septic Shock

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03014063's enrollment target sits among peer trials

18 23rd of 24 higher than 2 of 24 other Septic Shock trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Septic Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03014063, the US trial registry maintained by the National Library of Medicine. NCT03014063 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.